Pennsylvania Medicaid coverage for Mounjaro (Type 2

Medicaid

Covered with requirements

What you need to qualify

Prior trial of another GLP-1 medication (preferred GLP-1 receptor agonists approved for the beneficiary's diabetes diagnosis)

Qualification pathways

You can qualify through any one of these.

Non-preferred GLP-1 for diabetes — Mounjaro initial and renewal

All of:

Diagnosis of diabetes
The prescribed GLP-1 receptor agonist (Mounjaro/tirzepatide) is FDA-approved for the treatment of diabetes

Plus any one of:

History of therapeutic failure of the maximum FDA-approved dose of preferred GLP-1 receptor agonist(s) approved/medically accepted for the beneficiary's diagnosis
Contraindication to the maximum FDA-approved dose of preferred GLP-1 receptor agonist(s)
Intolerance to the maximum FDA-approved dose of preferred GLP-1 receptor agonist(s) (with chart documentation of troubleshooting over >= 1 month if switching due to intolerance)

Documentation to bring

Documentation of diabetes diagnosis
Documentation of therapeutic failure of preferred GLP-1(s) at maximum FDA-approved dose, OR contraindication or intolerance (with troubleshooting documentation over >= 1 month if intolerance-based: dietary changes, prescription antiemetics, dose adjustment)
Documentation that Mounjaro (tirzepatide) is FDA-approved for the treatment of diabetes
Documentation of age-appropriateness per FDA labeling, compendia, or peer-reviewed literature
Documentation of no contraindication to Mounjaro
If therapeutic duplication: documentation of intent to transition or medical reason for concomitant use

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for Renewal requires: (1) diagnosis of diabetes; (2) therapeutic failure of/contraindication to/intolerance to maximum FDA-approved dose of preferred GLP-1(s) for the beneficiary's diagnosis; (3) Mounjaro is FDA-approved for diabetes. No A1C or weight thresholds re-checked at renewal.

Not covered when

Overweight/obesity treatment indication excluded
Saxenda (liraglutide) not covered for any indication

Policy note: Mounjaro is non-preferred for diabetes on the PA MA PDL. Requires therapeutic failure of, contraindication to, or intolerance to the maximum FDA-approved dose of preferred GLP-1(s) for the beneficiary's diabetes diagnosis. For intolerance-based switching (e.g., from semaglutide to tirzepatide), must document that troubleshooting was tried over at least 1 month: dietary changes (apples, crackers, mint/ginger drinks 30 minutes after dosing), prescription antiemetics, and dose adjustment if lower doses were tolerated. Approval for up to 12 months. Prescriptions limited to 1-month supply per fill.

Policy effective January 1, 2026 · verified June 4, 2026 · source: mab2025112403.pdf

Pennsylvania Medicaid coverage for Mounjaro (Type 2 Diabetes)